LumiThera has closed $5.5 million in Series B financing to support development of its LT-300 device for treating dry age-related macular degeneration, according to a company press release.
The lead investor was WaterStone Capital, with RPR Venture as a co-investor.
Proceeds from the financing will be used to continue the company’s work obtaining regulatory clearances in Europe and additional countries outside of the United States.
“We are pleased with the investor interest in the company and have oversubscribed the Series B round,” Clark Tedford, PhD, president and CEO of
Uncategorized